TD Cowen has upgraded CRISPR Therapeutics (NASDAQ:CRSP) to hold from sell, stating it now sees less downside to the stock. "We believe Casgevy expectations have bottomed out in the near term and ...

TD Cowen analyst William Katz maintained a Hold rating on Artisan Partners (APAM – Research Report) today and set a price target of $46.00. The ...

In a report released today, Daniel Bergman from TD Cowen maintained a Buy rating on Primerica (PRI – Research Report), with a price target of ...

CRISPR Therapeutics (NASDAQ:CRSP) received an upgrade in its stock rating by analysts at TD Cowen, changing from Sell to Hold, while maintaining a price target of $35.00. The revision in the rating ...

On Tuesday, during a House Financial Services Committee hearing, U.S. lawmakers exhibited a divide in their approaches to regulating cryptocurrencies and stablecoins, highlighting the challenges in ...

Mr. Hutchison’s change came in the wake of Tuesday’s premarket release of fourth-quarter 2024 operating results and updated ...

Teledyne Technologies Incorporated (NYSE:TDY) today announced that George Bobb, President and Chief Operating Officer, and Jason VanWees, Vice Chairman, will present at the TD Cowen 46th Annual ...

Metagenomi is a precision genetic medicines company committed to developing curative therapeutics for patients using its ...

The TRADE sits down with TD Securities’ Carl Hayes, head of European cash equities, and James Baugh, managing director and ...

News of a significant price-target boost from an analyst tracking GDS Holdings ( GDS 7.20%) was the main catalyst behind the ...